Disitamab vedotin (brand name Aidixi in China, development code RC48) is an antibody-drug conjugate (ADC) developed by RemeGen for the treatment of various HER2-positive cancers.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.